Gilead's 90%

StephenW

Gilead's 90%


Gilead announced interim data from a Phase 2 trial (ATOMIC) examining a 12-week course of treatment with the once-daily nucleotide GS-7977 plus pegylated interferon and ribavirin in treatment-naive patients with genotype 1 hep C. The study found that 90% of patients achieved SVR 12-weeks post-treatment. These findings will be presented during an oral session at the 47th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2012) in Barcelona, Spain. "These data suggest that this GS-7977-based regimen could offer most patients with genotype 1 a simple, short, three-month course of treatment with very high cure rates," said Dr Kris Kowdley, Director of the Liver Center of Excellence at the Virginia Mason Medical Center in Seattle and the study's principal investigator.

Gilead公司的90％


Gilead公司宣布，从第2阶段试验研究与每天一次的核苷酸GS-7977加聚乙二醇干扰素在治疗过的患者利巴韦林基因型1 HEP C.研究发现，一个疗程12周的课程（原子）的中期数据，90 ％的患者获得SVR12周后治疗。这些调查结果将提交口头会议期间，在肝脏研究欧洲协会第47届年会在西班牙巴塞罗那（2012年国际肝病大会）。卓越的肝病中心主任的克里斯Kowdley博士说：“这些数据表明，这个GS-7977为基础的方案可以提供大多数患者基因型1一个简单的，短期的，三个月的治疗，具有很高的治愈率当然，”弗吉尼亚梅森医疗中心在西雅图和研究的主要研究者。